OOIR: Observatory of International Research

Papers

(The H4-Index of Blood Cancer Journal is 38. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Disparities in time to treatment with oral antimyeloma medications	245
Expanded tumor-associated polymorphonuclear myeloid-derived suppressor cells in Waldenstrom macroglobulinemia display immune suppressive activity	202
Correction: Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells	189
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine	136
In response to: Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study	121
Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia	111
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M	93
Genomic landscape of hyperleukocytic acute myeloid leukemia	92
Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma	89
Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor	84
Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes	80
Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma	79
Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT	78
Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study	73
A multiparametric niche-like drug screening platform in acute myeloid leukemia	70
Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma	68
BCR::ABL1-positive acute lymphoblastic leukemia as a high-risk feature of central nervous system relapse after allogeneic hematopoietic cell transplantation	66
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients	66
T-cell phenotype including CD57+ T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma	61
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib	58
Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease	55
Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort	54
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency	52
Common cardiovascular biomarkers can independently predict outcome of patients with Myelodysplastic syndromes	50
Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL	50

Dynamics of microcyst-like epithelial changes associated with Belantamab mafodotin therapy in a patient with multiple myeloma—a case report	50
Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management	49
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid	46
Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study	46
Should I stay or should I go (to transplant)? Managing insufficient responses to induction in multiple myeloma	43
CALRins5-mediated clonal hematopoiesis causes severe hemolytic anemia in a female PGK1Ser320Asn carrier	43
BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma	43
Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma	42
Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome	40
Venetoclax plus arsenic and all-trans retinoic acid in patients with relapsed/refractory acute promyelocytic leukemia	39
Assessing the performance of the Iceland screens, treats, or prevents multiple myeloma (iStopMM) model in a multicultural Bronx cohort: implications for monoclonal gammopathy of undetermined significa	39
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression	38
Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study	38
Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis	38